cTRL Therapeutics

www.ctrl-tx.com
Innovation Type:
Therapeutics
Cancer Type:
Multiple
Funding Stage:
Seed
Fund:
Compass Rose
Harnessing the power of cTRLs (circulating tumor-reactive lymphocytes) in the blood to unlock the next generation of solid tumor cancer therapies.

Related news

CTRL Therapeutics, a FACIT-backed start-up, raises US$10M to develop autologous cell therapy for patients living with cancer

CTRL Therapeutics ("CTRL") closed a seed financing round to develop a tumor-infiltrating lymphocyte (TIL) therapy for solid tumours. CTRL is advancing novel, non-invasive and less costly therapies for patients living with cancer. Read More

cTRL Therapeutics announces new Chief Executive Officer to continue advancing its novel immune cell therapy

cTRL Therapeutics ("cTRL"), a FACIT co-founded and financed company developing novel tumour cell therapies for patients living with cancer, welcomes industry veteran Derrell D. Porter, M.D., as Chief Executive Officer. Read More

FACIT generates $1.5 billion in follow-on investment

FACIT announced $1.5 billion in follow-on investment attracted to its portfolio of cancer biotechnology start-ups in Ontario, a significant milestone for life science commercialization in Canada. Read More

FACIT and University of Toronto launch precision medicine company: Cellular Analytics

October 30, 2019 – Cellular Analytics is founded upon a proprietary microfluidic platform that enables molecular characterization of cancer at the level of single circulating tumour cells. Read More

FACIT welcomes life sciences executive Ken Newport to its Board; Director Shana Kelley appointed to the Order of Ontario

January 26, 2021 – Mr. Newport is a passionate executive and advocate of Ontario’s life science sector, having decades of leadership experience in both public and private ventures. Read More

High-potency TIL cell therapy approach reported using CytoFind platform developed by FACIT portfolio company Cellular Analytics

January 27, 2022 – FACIT congratulates portfolio company Cellular Analytics on a recent publication by its CSO, Dr. Shana Kelley and collaborators, on the Company’s tumor-infiltrating lymphocyte (TIL) therapeutics platform. Read More

    CONNECT WITH FACIT

    Learn more about how we are driving made-in-Ontario oncology innovations reach the market.